Nevro EBITDA Margin 2013-2022 | NVRO

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Nevro (NVRO) over the last 10 years. The current EBITDA margin for Nevro as of June 30, 2022 is .
Nevro EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-06-30 $0.39B $-0.11B -29.38%
2022-03-31 $0.39B $-0.10B -26.68%
2021-12-31 $0.39B $-0.09B -23.00%
2021-09-30 $0.39B $-0.06B -15.74%
2021-06-30 $0.41B $-0.02B -4.16%
2021-03-31 $0.36B $-0.03B -9.37%
2020-12-31 $0.36B $-0.04B -10.80%
2020-09-30 $0.37B $-0.05B -12.88%
2020-06-30 $0.36B $-0.07B -18.21%
2020-03-31 $0.40B $-0.06B -15.95%
2019-12-31 $0.39B $-0.08B -21.28%
2019-09-30 $0.38B $-0.09B -23.18%
2019-06-30 $0.38B $-0.08B -21.58%
2019-03-31 $0.38B $-0.06B -16.75%
2018-12-31 $0.39B $-0.04B -9.79%
2018-09-30 $0.38B $-0.03B -8.20%
2018-06-30 $0.36B $-0.03B -7.42%
2018-03-31 $0.35B $-0.03B -8.38%
2017-12-31 $0.33B $-0.03B -8.28%
2017-09-30 $0.30B $-0.03B -10.70%
2017-06-30 $0.28B $-0.03B -10.43%
2017-03-31 $0.26B $-0.03B -10.20%
2016-12-31 $0.23B $-0.02B -9.61%
2016-09-30 $0.19B $-0.03B -15.18%
2016-06-30 $0.15B $-0.05B -31.72%
2016-03-31 $0.10B $-0.06B -58.42%
2015-12-31 $0.07B $-0.06B -89.86%
2015-09-30 $0.05B $-0.06B -121.74%
2015-06-30 $0.04B $-0.04B -110.00%
2015-03-31 $0.04B $-0.03B -86.49%
2014-12-31 $0.03B $-0.03B -79.41%
2014-06-30 $0.02B $-0.02B -90.48%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.548B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $204.040B 20.78
Edwards Lifesciences (EW) United States $52.534B 37.17
Alcon (ALC) Switzerland $29.415B 24.91
STERIS (STE) Ireland $16.731B 20.78
Teleflex (TFX) United States $9.732B 15.51
Fresenius Medical Care AG KGaA (FMS) Germany $8.433B 7.78
Penumbra (PEN) United States $7.007B 840.64
Globus Medical (GMED) United States $5.801B 29.59
Glaukos (GKOS) United States $2.385B 0.00
Integer Holdings (ITGR) United States $2.051B 16.04
Paragon 28 (FNA) United States $1.343B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.035B 15.85
Artivion (AORT) United States $0.537B 51.19